Molecular structure of Valsartan, CAS Number: 137862-53-4
Valsartan (CAS 137862-53-4)
See product citations (4)
Alternate Names:
N-(1-Oxopentyl)-N-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-L-valine
Application:
Valsartan is a nonpeptide angiotensin II AT1 receptor antagonist
CAS Number:
137862-53-4
Purity:
≥98%
Molecular Weight:
435.52
Molecular Formula:
C24H29N5O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Valsartan is in a class of angiotension receptor blockers (ARBs) particularly a nonpeptide AT1 (angiotensin II AT1-receptor) antagonist. This causes changes on biochemical processes that stem from this receptor with a variety of effects. Valsartan serves as a tool in understanding the renin-angiotensin system (RAS). Research involving valsartan can help elucidate the complex interactions within RAS. Investigating the molecular interactions between valsartan and the AT1 receptor contributes to the broader understanding of receptor-ligand dynamics. The environmental impact of valsartan, particularly its persistence and bioactivity in water systems, is a growing area of study.
Valsartan (CAS 137862-53-4) References
- Efficacy of Sacubitril/Valsartan in Hypertension. | Malik, AH. and Aronow, WS. Am J Ther. 29: e322-e333. PMID: 30664018
- Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF. | McMurray, JJV., et al. 2020. Circulation. 141: 338-351. PMID: 31736337
- Indoxyl sulfate impairs valsartan-induced neovascularization. | Kuo, KL., et al. 2020. Redox Biol. 30: 101433. PMID: 31972507
- Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes. | Khan, MS., et al. 2021. JACC Heart Fail. 9: 137-145. PMID: 33309581
- Effect of Sacubitril/Valsartan Combined with Dapagliflozin on Long-Term Cardiac Mortality in Heart Failure with Reduced Ejection Fraction. | Karabulut, U., et al. 2022. Angiology. 73: 350-356. PMID: 34560822
- Pharmacokinetics and Pharmacodynamics of Sacubitril/Valsartan in Maintenance Hemodialysis Patients with Heart Failure. | Feng, Z., et al. 2022. Blood Purif. 51: 270-279. PMID: 34753147
- Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. | Pfeffer, MA., et al. 2022. Circulation. 145: 87-89. PMID: 34797725
- Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan: A Pooled Analysis of EVALUATE-HF and PROVE-HF. | Myhre, PL., et al. 2022. JACC Heart Fail. 10: 119-128. PMID: 35115085
- Sacubitril/valsartan attenuates atrial structural remodelling in atrial fibrillation patients. | Yang, L., et al. 2022. ESC Heart Fail. 9: 2428-2434. PMID: 35437929
- Efficacy and safety of sacubitril/valsartan in the treatment of middle-aged and elderly patients with hypertension: a systematic review and meta-analysis of randomized controlled trials. | Wu, HX., et al. 2022. Ann Palliat Med. 11: 1811-1825. PMID: 35672897
- Effect of Sacubitril/Valsartan on renal function in patients with chronic kidney disease and heart failure with preserved ejection fraction: A real-world 12-week study. | Jia, R., et al. 2022. Eur J Pharmacol. 928: 175053. PMID: 35709921
- Cost-benefit analysis of sacubitril/valsartan in a Medicaid population. | Gabot, A., et al. 2022. Am J Manag Care. 28: 349-352. PMID: 35852884
- Genotoxicity evaluation of a valsartan-related complex N-nitroso-impurity. | Glowienke, S., et al. 2022. Regul Toxicol Pharmacol. 134: 105245. PMID: 35988810
- Effect of sacubitril/valsartan and ACEI/ARB on glycaemia and the development of diabetes: a systematic review and meta-analysis of randomised controlled trials. | Wang, R., et al. 2022. BMC Med. 20: 487. PMID: 36527023
Inhibitor of:
1700095B22Rik, AGT1, AGTRAP, ANG III, ANG IV, Angiotensin, AP1AR, AT1, AT1a, DGCR14, ESM-1, GRK 6, kallistatin, KCC1, Klkb16, MAS1L, Myotrophin, OATP-H, Olfr1023, Olfr1030, Olfr1049, Olfr1056, Olfr1095, Olfr1100, Olfr770, Olfr771, Olfr829, Olr1472, Olr1479, Olr1499, Olr1511, Olr1517, Olr1590, Olr20, Olr222, Olr24, Olr251, Olr400, Olr401, Olr402, Olr409, Olr413, Olr415, Olr418, Olr419, Olr421, Olr434, Olr853, RENBP, S-antigen, SLC26A11, SNAT3, V1RA5, V1RA6, V1RA9, V2R11, WNK1, and WNK3.Activator of:
ANG IV, AT1, AT1a, CYP2C9, ET-3, GLOD5, Klk26, MEF-2A, NFATc3, NPR-C, PC-1, and Renin-1.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Valsartan, 10 mg | sc-220362 | 10 mg | $39.00 | |||
Valsartan, 100 mg | sc-220362A | 100 mg | $90.00 | |||
Valsartan, 1 g | sc-220362B | 1 g | $120.00 |